Ibtissam Marchiq

Statistics

Publications

Citations

175

H-Index

Active since

2022

Affiliations

Massachusetts General Hospital(Current)

Institut de Relations Internationales et Stratégiques

King's College Hospital NHS Foundation Trust

The University of Texas MD Anderson Cancer Center

Institut des Hautes Études Scientifiques

Ibtissam Marchiq is an author at Massachusetts General Hospital specializing in allogeneic car t-cell therapy, cancer immunotherapy, and refractory acute lymphoblastic leukemia.

Publications per year

2022–2022

Publications

UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial

Reuben Benjamin, Nitin Jain, Marcela V. Maus et al. · The Lancet Haematology · 2022 · 136 citations · Full text

Life Sciences, Hematology, Immunology +14

Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia

Sandra Dupouy, Ibtissam Marchiq, Thibaud Derippe et al. · Cancer Research Communications · 2022 · 22 citations · Full text

Life Sciences, Pharmacokinetics, Pharmacology +17

Mechanistic Modeling of the Interplay Between Host Immune System, IL-7 and UCART19 Allogeneic CAR-T Cells in Adult B-cell Acute Lymphoblastic Leukemia

Thibaud Derippe, Sylvain Fouliard, Ibtissam Marchiq et al. · Cancer Research Communications · 2022 · 17 citations · Full text

Pharmacy, Immunology, Pharmacokinetics +16

1–3 of 3